Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas

Gene Therapy

Volumn 14, Issue 22, 2007, Pages 1573-1586

  Wei, J ^a   Wahl, J ^a   Nakamura, T ^b   Stiller, D ^c   Mertens, T ^a   Debatin, K M ^a   Beltinger, C ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b Mayo Clinic College of Medicine   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MEASLES VIRUS; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR CELL; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; BRAIN NEOPLASMS; BYSTANDER EFFECT; CELL LINE, TUMOR; CELLS, CULTURED; CYTOPATHOGENIC EFFECT, VIRAL; ENDOTHELIAL CELLS; GENE THERAPY; GLIOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MEASLES VIRUS; MICE; MICE, KNOCKOUT; ONCOLYTIC VIROTHERAPY; RANDOM ALLOCATION; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MEASLES VIRUS; MUS;

EID: 35848942827     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303027     Document Type: Article

References (33)

1. Nakamura T, Russell SJ. Oncolytic measles viruses for cancer therapy. Expert Opin Biol Ther 2004; 4: 1685-1692.
2. Fielding AK. Measles as a potential oncolytic virus. Rev Med Virol 2005; 15: 135-142.
3. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993; 75 295-305.
4. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C et al. Human membrane cofactor protein (CD46) acts as a cellular receptbr for measles virus. J Virol 1993, 67 6025-6032.
5. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as, a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63: 2462-2469.
6. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolylic measles virus. Cancer Res M04; 64: 4919-4926.
7. Firsching R, Buchholz CJ, Schneider U, Cattaneo R, ter Meulen V, Schneider-Schaulies J. Measles virus spread by cell-ell contacts: uncoupling of contact-mediated receptor (CD46) downregulation from virus uptake. J Virol 1999, 73: 5265-5273.
8. Duprex WP, McQuaid S, Roscic-Mrkic B, Cattaneo R, McCallister C, Rima BK. In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J Virol 2000; 74: 7972-7979.
9. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001; 97: 3746-3754.
10. Esolen LM, Park SW, Hardwick JM, Griffin DE. Apoptosis as a cause of death in measles virus-infected cells. J Virol 1995; 69: 3955-3958.
11. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
12. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656-4662.
13. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cance Res 2006; 12: 1868-1875.
14. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006; 66: 7694-7700.
15. Heinzerling L, Kunzi V, Oberholzer PA, Kundig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005; 106: 2287-2294.
16. Jarmy G, Wei J, Debatin KM, Beltinger C. Apoptosis-inducing cellular vehicles for cancer gene therapy: Endothelial and neural progenitors. In: Srivastava R (ed). Apoptosis, Cell Signaling and Human Diseases: Molecular Mechanism. Humana Press Inc.: Totowa, 2006, pp 279-302.
17. Ferrari N, Glod J, Lee J, Kobiler D, Fine HA. Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. Gene Therapy 2003; 10: 647-656.
18. Tabatabai G, Bahr O, Mohle R, Eyupoglu IY, Boehmler AM, Wischhusen J et al. Lessons from the bone marrow: How malignant glioma cells attract adult haematopoietic progenitor cells. Brain 2005; 128 2200-2211.
19. Tabatabai G, Frank B, Mohle R, Weller M, Wick W. Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. Brain 2006; 129: 2426-2435.
20. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000, 105: 71-77.
21. Wei J, Jarmy G, Genuneit J, Debatin KM, Beltinger C. Human blood late outgrowth endothelial cells for gene therapy of cancer: Determinants of efficacy. Gene Therapy 2006; 14: 344-356.
22. Schnorr JJ, Dunster LM, Nanan R, Schneider-Schaulies J, Schneider-Schaulies S, ter Meulen V. Measles virus-induced down-regulation of CD46 is associated with enhanced sensitivity to complement-mediated lysis of infected cells. Eur J Immunol 1995; 25: 976-984.
23. Wei J, Zhou S, Bachem MG, Debatin KM, Beltinger C. Infiltration of blood outgrowth endothelial cells into tumor spheroids: Role of matrix metalloproteinases and irradiation. Anticancer Res 2007; 27: 1415-1421.
24. Peng KW, Hadac EM, Anderson BD, Myers R, Harvey M, Greiner SM et al. Pharmacokinetics of oncolytic measles virotherapy: Eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther 2006; 13: 732-738.
25. Grote D, Cattaneo R, Fielding AK. Neutrophils contribute to the measles virus-induced antitumor effect: Enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res 2003; 63: 6463-6468.
26. Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res 2005; 65: 5292-5300.
27. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5: 1523--1537.
28. Jevremovic D, Gulati R, Hennig I, Diaz RM, Cole C, Kleppe L et al. Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. Am J Physiol Heart Circ Physiol 2004; 287: H494-H500.
29. Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005; 11: 1073-1081.
30. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006; 311: 1780-1784.
31. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W et al. Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97: 12846-12851.
32. Duprex WP, McQuaid S, Hangartner L, Billker MA, Rima BK. Observation of measles virus cell-to-cell spread in astrocytoma-cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999; 73: 9568-9575.
33. Beltinger C, Fulda S, Walczak H, Debatin KM. TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells. Cancer Gene Ther 2002; 9: 372-381.